Nanoform completes share issue
Helsinki-based nanoparticle medicine specialist Nanoform has completed a new share issue, in the process raising about €25 million from global and Nordic institutional investors. This will mainly be used to build a GMP manufacturing site in the US, where most of the company’s customers are.
The company said that it “continues to be committed to the strong execution of its communicated strategy”, having reached all its near-term targets for 2021 and being on track to deliver on its targets for 2022. The funding from an IPO it did in 2020 and the new share issue were said to be “sufficient for the growth strategy” it has outlined.
RELATED ARTICLES
Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4.
Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU.
EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.
W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.
Noramco, an API supplier specialised in controlled substances, has launched Noramco Group, which it describes as a “comprehensive North American-based supply chain solution” for clinical and commercial APIs and drug products. Noramco Group unites the capabilities of three subsidiaries:
